Aquestive Therapeutics (AQST) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.12
- Surprise
- —
- Revenue (period 2026-06-30)
- $13.8M
- Score at report (before → after)
- 6.2 → 6.2/10
Revenue source: xbrl.
How the report landed
TrendMatrix's engine moved from Sell (6.2/10) to Buy (Wait) at 6.2/10 after the report.
Coverage in the report window
- Aquestive Therapeutics Q2 EPS $(0.18) Misses $(0.12) Estimate, Sales $13.819M Beat $11.418M Estimate — benzinga, 2026-08-11
- Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $50.584M Est — benzinga, 2026-08-11
- Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study — benzinga, 2026-08-10
Where TrendMatrix's rating stands now
TrendMatrix currently rates AQST Sell at 5.6/10.
1 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-04.
What argues against it
- Concentration risk — Product: Suboxone
- Quality below floor (3.9 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $4.61
- Price target
- $8.12
- Stop
- $4.29
- Upside to target
- +76.1%
- Reward-to-risk
- 7.9:1
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
AQST at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $578.6M
- P/E (fwd)
- -8.1
- 52-week range
- $2.93–$7.55
- Off 52-week high
- 38.9%
- RSI (14)
- 43
- Volume vs avg
- 0.53×
- Score today
- 5.6/10